European Commission Reaches First Agreement on Potential COVID-19 Vaccine With AstraZeneca

Marco Green
August 15, 2020

Johnson iamp; Johnson's COVID-19 vaccine candidate Ad26.COV2.S.is now in Phase 1/2 clinical trials, BE said in a statement.

The deals include an initial 60 million doses of Novavax's vaccine and 30 million doses of J&J's vaccine.

J&J said it has also agreed to collaborate with the United Kingdom government on a global Phase 3 trial to explore the two-dose regimen of its vaccine candidate.

No vaccine has yet proven to work, but more than 20 candidates are in clinical trials.

It will run parallel to the Phase 3 trial investigating the single-dose program.

Twenty-eight vaccine candidates are now in human trials, according to the World Health Organization, as the global death toll from the novel coronavirus nears 750,000.

The deal, made with the pharmaceutical company AstraZeneca, would secure the purchase of at least 300 million doses on behalf of the European Union member states.

The trial will be a study in about 9,000 adults between 18 years and 85 years of age.

Supported by the government, another vaccine development company Novavax will conduct a Phase 3 clinical trial of its vaccine working with Britain's National Institute for Health Research (NIHR) to access their clinical network and expertise.

In July 2020, interim results from the ongoing Phase I/II COV001 trial were published in The Lancet and showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.

Friday's announcement follows earlier ones that confirmed the conclusion of exploratory talks for vaccines supply with Sanofi-GSK on July 31 and with Johnson & Johnson on August 13.

British citizens will receive early access to 90 million doses of the two COVID-19 vaccine candidates should they prove safe and effective.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER